This question of whether immunotherapy benefits PD-L1-positive hormone-receptor positive breast cancer will be better answered by the ongoing randomized trial of the antibody drug conjugate sacituzumab govitecan ± pembrolizumab in 110 patients with PD-L1-positive metastatic hormone receptor-positive breast cancer (NCT04448886). This evidence concerns the gene NR4A1 and breast carcinoma.